Apricus Licenses Its Own Drug Back From Allergan
This article was originally published in Scrip
Executive Summary
Apricus Biosciences successfully confused its investors on Sept. 10 when the San Diego-based company announced that it managed to license its own topical treatment for erectile dysfunction (ED) from Allergan for a meager $1m upfront payment plus a future $1.5m regulatory milestone fee.
You may also be interested in...
Apricus Won't Need New Trials To Resubmit ED Cream Vitaros At FDA
After feedback on a very old complete response, biotech plans to resubmit a filing in the second half of 2017, instead of the fourth quarter, and will need to engage the Office of Product Quality because Vitaros is viewed as a drug/device combination.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.